Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
We are coming up to 7 weeks come this Good Friday since VS declared clinical Trials would be "commencing in a few months". We should not get into the semantics of what "a few" means, other than to say, we are close. Perhaps too close for comfort for the share borrowers who live beyond the skirting boards and in the wall cavity's, bit like vermin I guess . Penn University are the first hospital to sign up for the trials with an agreement in place already. I suspect Penn with their renowned reputation, will be a catalyst for other hospitals to be queuing up eager to be involved and sharing in a part of any success. There's another climb after another fall to endure but Everest wasn't cracked first time and I would rather be here now with an eye set on this particular summit. GLA
Fully understand the sentiment Mr India. Its a bit like the players that take a non league team to the cusp of being a Premiership club and then seeing a raft of new players coming in to share the spoils. However, without new blood eager to buy shares and make a profit, we might end reach the dizzy heights WE ALL desire. So, new investors, you are very welcome but stick around for a few seasons for a 1000% . Don't be selling out too soon and leaving us older players (lth's) to pick up the pieces to keep this Hemo club afloat AGAIN. GLA (from an ageing fullback)
Https://www.reuters.com/world/americas/dengue-outbreak-argentina-track-break-records-2024-03-20/
Dengue record breaking outbreak in Argentina. Time to get in there with CBR and seek funding and approvals assistance to sort this epidemic out. It was achieved with the Covid vaccines why not with CBR. C'mon Vlad.
Dhub, I have always followed your posts with interest so kind of found it relatively easy to see when there was a slight change in your sentiment for Hemo. I am sure it wasn't wholly obvious to the casual observer but to a regular reader it was very clear. However, on the 9th you felt that discussion with large Pharma had been taking place but it did not break in time and postulated that you felt something might happen in a couple of weeks. By this Friday that couple of weeks will come to an end. Given that you have reduced your holding combined with your prediction and regular mention of FOMO Friday, I wonder that if news breaks you may be in danger of missing out yourself with a diminished holding. Is FOMO something you have considered yourself. It would be a terrible tragedy given the years you have held firm. I do appreciate everyone has their own reason to sell. GL
Https://www.labiotech.eu/in-depth/us-biotech-investment/
This is an interesting article but if reading suggest read all of it. We know the challenges and acknowledge the history and it all clearly resonates with the path Hemogenyx has trodden. However, VS has got through those difficulties with well developed science and fantastic potential. He mentioned being lean and this is referenced. He has raised funds in an early stage biotech environment cited as difficult and has a humdinger of a biotechnology platform in CBR. It won't need much for this coiled spring to leap into action. There's a breeze and tumbleweed at the moment but I think next news will likely be great news, a real catalyst. Sit tight I say, let this time to the heavy lifting. GLA
Dr Sandler said in the II interview that he was going to make a "significant amount of money"💰 for me as an investor as well asv"save lives" told me mortgage people and everything!..don't they say when investing let time do the heavy lifting. It's simply a matter of time now and given time now clinical he will deliver. The science is progressing very well. GLA
Https://www.forbes.com/sites/forbesbusinesscouncil/2024/03/15/strategizing-biotech-partnerships-to-help-bring-therapies-to-patients/
When you read this article we should be comforted that VS has got the Clinical Trials partnership right and manufacturing infrastructure right It's the finance partnership that needs some work but early success in CT's might secure what HEMO need on favourable terms. Goodnight all & hang in there, HEMO can do this.
Https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-panel-votes-favor-expanded-use-bristol-myers-car-t-therapy-2024-03-15/
An advisory panel met with the FDA today and in a vote 8 to 3 voted in favour of Bristol Myers Sqibb expanding their use of a CAR T therapy for a myeloma condition they are treating. There has been reports about concerns with CAR T but this is a further endorsement of the CRT T based therapies. This is not a ramp for BMS but shoes that yhe FDA recognise that this is a developing therapy which even if not perfect they see fit to allow expansion of its use. This bodes well for Hemo in it's clinical trials. HEMO CAR T is well researched, has approval and can deliver the efficacy required knowing that even big pharma sre not perfect. I will drop another couple of articles for anyone who might be interested. GLA
Always good to hear about the science and it's potential. A great reminder of what could be Haywain.
I was dreading talking to my wife about the run down barn in France which we could buy as a doer upper. Particularly having already managed expectations by dissuading her that the Chateau we had our eyes on was perhaps too much and a Gites might be better. If its looking like a sleeping back under Pont Neuf because I cannot get enough out of Hemo for even a ramshackle barn, then I am toast, or rather croissant in this case. Bon chance everyone, I think we will do okay.
To the shareholders and the onlookers things seem to be in a little bit of disarray. This is fueled heavily by more recent events. Time for the company to grab back control, reset their vision and goals and layout for people (those with money in the company already or any potential prospects) what the strategy is going to be.
Yes, there are a lot of what if's and we know that, but a sense that they know where they are going and how to get there is imperative to avoid any perception of drift which many will take advantage of.
A clear and concise communication is needed right now. GLA
It's history now I guess but the VS tweet some weeks back. just wondering whether this was perhaps in reference to internal wrangling over funding. Maybe alternative funding was available but VS wanted to maintain control a little longer through Phase 1. Therefore, an argument internally the "he won!" I hope we can recover somewhat next week.
Moving forward, any thoughts saying on CBR Patent Approval timescales? GLA
What more can be said about today? The only silver lining is that today is the 29th February, so there will only be a 4 yearly reminder of what took place...this time.....year! Think we should lobby to change it from "leap year" to "plunge year". We'll get there, eventually I am sure but perhaps not with some of the people we should be arriving with. who had simply had enough. GLA
Is it a possibility that some institutions holding small amounts (to them 10+ million shares say) could be selling enough to put downward pressure on the price and lowering the cost of entry when funding news breaks. So they do not yet commit the big money in advance of JV or funding news but in the meantime cushion future investment cost on say much larger investments. Effectively, they have held the price down by chipping in what is to them small offloads. It would fit as even the most cynical about funding must be bewildered by the static share price and the obvious disconnect between going clinical and the current sp. You don't get major offloading of shares on great news without a reason. Funding requirements have always been there. The funding issues now with clinical go ahead are far less a concern and institutions will know this, they are just not showing their hand other than dropping in sales to keep their much bigger buys (on news) as cheap as possible. GLA
HH - I agree, let's hope we get to the stage of setting a date. Although to be fair what other forum do we have if noone else is really talking to the private investors. Once we start to get a regular flow of updates through clinical trials from the company, there will be less need to speculate on boards like these. GLA